In fiscal 2026, which ended Apr 30, 2026, Pharmacyte Biotech, Inc. reported revenue of $0. It recorded a net loss of $19.4 million. Diluted earnings per share were -$2.77. Over the twelve months ended Jul 31, 2026, revenue was $0 and the net loss was $16.1 million.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jul 31, 2026
|
FY 2026
Apr 30, 2026
|
FY 2025
Apr 30, 2025
|
FY 2024
Apr 30, 2024
|
FY 2023
Apr 30, 2023
|
FY 2022
Apr 30, 2022
|
FY 2021
Apr 30, 2021
|
FY 2020
Apr 30, 2020
|
FY 2019
Apr 30, 2019
|
FY 2018
Apr 30, 2018
|
FY 2017
Apr 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and development |
0
-18.6%
|
0
-10.7%
|
0
+7.6%
|
0
-13.0%
|
0
-32.2%
|
1
-24.6%
|
1
+204.2%
|
0
-34.5%
|
0
-77.0%
|
2
+69.0%
|
1
-16.0%
|
| Selling, general and administrative |
5
+45.1%
|
5
+24.7%
|
4
-35.6%
|
6
+449.4%
|
1
+2.0%
|
1
+160.8%
|
0
-64.0%
|
1
-15.7%
|
1
-24.2%
|
2
+144.2%
|
1
-67.5%
|
| Operating income |
-7
-77.2%
|
-7
-56.6%
|
-4
+48.6%
|
-9
-32.0%
|
-6
-47.0%
|
-4
-21.2%
|
-4
+5.3%
|
-4
+6.7%
|
-4
+41.3%
|
-7
-57.2%
|
-4
+26.9%
|
| Income tax |
—
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Net income |
-16
-1334.7%
|
-19
-163.4%
|
31
+9085.0%
|
0
+107.7%
|
-4
-1.8%
|
-4
-19.4%
|
-4
+7.2%
|
-4
+5.9%
|
-4
+40.4%
|
-7
-53.7%
|
-4
+26.7%
|
| Net income to common |
-21
-269.4%
|
-23
-199.3%
|
23
+235.5%
|
-17
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Basic EPS |
-2.20
-178.6%
|
-2.77
-186.8%
|
3.19
+277.2%
|
-1.80
-718.2%
|
-0.22
+18.5%
|
-0.27
|
—
|
—
|
—
|
—
|
—
|
| Diluted EPS |
-2.20
-178.6%
|
-2.77
-186.8%
|
3.19
+277.2%
|
-1.80
-718.2%
|
-0.22
+18.5%
|
-0.27
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
9
+32.6%
|
8
+14.3%
|
7
-23.5%
|
10
-50.8%
|
19
+25.6%
|
16
+971.7%
|
1
+60.2%
|
1
-99.9%
|
1,100
+13.6%
|
969
+14.6%
|
845
+12.3%
|
| Weighted average shares, diluted |
9
+32.6%
|
8
+14.3%
|
7
-23.5%
|
10
-50.8%
|
19
+25.6%
|
16
+971.7%
|
1
+60.2%
|
1
-99.9%
|
1,100
+13.6%
|
969
+14.6%
|
845
+12.3%
|
| Other measures | |||||||||||
| Interest coverage |
—
|
—
|
—
|
—
|
—
|
-8,628.71x
|
-1,189.42x
|
-8,446.79x
|
—
|
—
|
-2,886.38x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PMCB (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1157075
- Former names
- NUVILEX, INC. (until Jan 9, 2015); EFOODSAFETY COM INC (until Mar 17, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.